SMPD1

Across TCGA pan-cancer cohorts, SMPD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMPD1 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMPD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMPD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where SMPD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	0.830	0.198	.024	12	view →
GBM	OS	Tertile	All	0.312	0.654	.007	6	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.216	.006	5	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	3	view →
UCEC	OS	Tertile	All	1.000	0.874	.034	2	view →
PDAC	OS	Median	II,III,IV	0.497	0.291	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMPD1–CCRCC (OS)

Open the CCRCC breakdown →